New Delhi, Mar 12 (PTI) Healthcare firm AstraZeneca Pharma on Thursday said it has received approval from India's drug regulator to market Acalabrutinib 100mg capsules, a medicine for treatment of chronic lymphocytic leukaemia.

"This is to inform that AstraZeneca Pharma India Limited has received import and market permission...from the Drugs Controller General of India for Acalabrutinib 100mg capsules," the company said in aBSE filing.

The receipt of this permission paves way for the launch of the capsules in India, subject to the receipt of related statutory approvals and licences, it said.

The capsule "is indicated for treatment of patients with chronic lymphocytic leukaemia/ small lymphocytic lymphoma", it added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)